Takaori, K., Bassi, C., Biankin, A., Brunner, T. B., Cataldo, I., Campbell, F., Cunningham, D., Falconi, M., Frampton, A. E., Furuse, J., Giovannini, M., Jackson, R., Nakamura, A., Nealon, W., Neoptolemos, J. P., Real, F. X., Scarpa, A., Sclafani, F., Windsor, J. A., Yamaguchi, K., Wolfgang, C., Johnson, C. D., Grp, Iap Epc Study (2016) International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. PANCREATOLOGY, 16 (1). pp. 14-27. ISSN 1424-3903

Full text not available from this repository.

Abstract

Background: Pancreatic cancer is one of the most devastating diseases with an extremely high mortality. Medical organizations and scientific societies have published a number of guidelines to address active treatment of pancreatic cancer. The aim of this consensus review was to identify where there is agreement or disagreement among the existing guidelines and to help define the gaps for future studies. Methods: A panel of expert pancreatologists gathered at the 46th European Pancreatic Club Meeting combined with the 18th International Association of Pancreatology Meeting and collaborated on critical reviews of eight English language guidelines for the clinical management of pancreatic cancer. Clinical questions (CQs) of interest were proposed by specialists in each of nine areas. The recommendations for the CQs in existing guidelines, as well as the evidence on which these were based, were reviewed and compared. The evidence was graded as sufficient, mediocre or poor/absent. Results: Only 4 of the 36 CQs, had sufficient evidence for agreement. There was also agreement in five additional CQs despite the lack of sufficient evidence. In 22 CQs, there was disagreement regardless of the presence or absence of evidence. There were five CQs that were not addressed adequately by existing guidelines. Conclusion: The existing guidelines provide both evidence- and consensus-based recommendations. There is also considerable disagreement about the recommendations in part due to the lack of high level evidence. Improving the clinical management of patients with pancreatic cancer, will require continuing efforts to undertake research that will provide sufficient evidence to allow agreement. Copyright (C) 2015, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved.

Item Type:	Review Article
Authors (ICR Faculty only):	Cunningham, David
All Authors:	Takaori, K., Bassi, C., Biankin, A., Brunner, T. B., Cataldo, I., Campbell, F., Cunningham, D., Falconi, M., Frampton, A. E., Furuse, J., Giovannini, M., Jackson, R., Nakamura, A., Nealon, W., Neoptolemos, J. P., Real, F. X., Scarpa, A., Sclafani, F., Windsor, J. A., Yamaguchi, K., Wolfgang, C., Johnson, C. D., Grp, Iap Epc Study
Additional Information:	ISI Document Delivery No.: DE8MF Times Cited: 0 Cited Reference Count: 133 Takaori, Kyoichi Bassi, Claudio Biankin, Andrew Brunner, Thomas B. Cataldo, Ivana Campbell, Fiona Cunningham, David Falconi, Massimo Frampton, Adam E. Furuse, Junji Giovannini, Marc Jackson, Richard Nakamura, Akira Nealon, William Neoptolemos, John P. Real, Francisco X. Scarpa, Aldo Sclafani, Francesco Windsor, John A. Yamaguchi, Koji Wolfgang, Christopher Johnson, Colin D. Ministry of Education, Culture, Sports, Science, and Technology, Japan [25462110]; Italian Ministry of Health [CUPJ33G13000210001] The authors thank all participants who gave productive comments to this work at the 46th European Pancreatic Club (EPC) Meeting, which was combined with International Association of Pancreatology (IAP) Meeting 2014 in Southampton. We thank Ms. Yu Aimi for clerical assistances. This work was supported in part by the Scientific Research (C) 25462110 grants from the Ministry of Education, Culture, Sports, Science, and Technology, Japan and by the Italian Ministry of Health CUPJ33G13000210001 grant to Fondazione Italiana Malattie del Pancreas (FIMP). 0 KARGER BASEL PANCREATOLOGY
Uncontrolled Keywords:	Pancreatic cancer Guidelines Pathology Chemotherapy Surgery Radiation PHASE-III TRIAL INTENSITY-MODULATED RADIOTHERAPY RANDOMIZED CONTROLLED-TRIAL NUCLEOSIDE TRANSPORTER 1 LONG-TERM SURVIVAL LYMPH-NODE RATIO COMMON BILE-DUCT RESECTION MARGIN FOLINIC ACID ADJUVANT CHEMOTHERAPY
Research teams:	Clinical Units > Gastrointestinal Unit
Depositing User:	Barry Jenkins
Date Deposited:	23 Mar 2016 14:34
Last Modified:	23 Mar 2016 14:34
URI:	http://publications.icr.ac.uk/id/eprint/14891

Actions (login required)

View Item